Products for Research Use Only
RegisterLogin

Nafamostat

CAT: 0804-HY-B0190-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0190-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nafamostat, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat has anticancer and antivirus effect. Nafamostat induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1) . Nafamostat can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].
CAS Number
81525-10-2
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; Flavivirus; NF-κB; Ser/Thr Protease; TNF Receptor
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease; NF-κB
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/nafamostat.html
Solubility
10 mM in DMSO
Smiles
O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3
Molecular Formula
C19H17N5O2
Molecular Weight
347.37
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175) ‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109 (10) : 2142-2153.|[2]Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94 (5) : 699-704.|[3]Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.|[4]Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30 (3) : 644-650.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
NF-κB
Citation 01
Biomolecules. 2022 Jul 31;12 (8) :1063.|Cells. 2022 Jan 18;11 (3) :319.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Patent. US20230210807A1.|Adv Healthc Mater. 2025 Aug 1:e02156.|Antiviral Res. 2023 Jun:214:105606.|bioRxiv. 2024 October 09.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Res. 2020 Mar;30 (3) :269-271.|Eur J Pharmacol. 2022 Mar 15:919:174795.|Eur J Pharmacol. 2023 Jan 5:938:175394.|Exp Mol Med. 2024 Dec;56 (12) :2631-2641.|Nat Chem Biol. 2022 Sep;18 (9) :963-971.|Nat Commun. 2024 Jun 27;15 (1) :5458.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Res Sq. 2025 Apr 07.|Viruses. 2022 Sep 12;14 (9) :2017.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.

Alternative Products

CatalogName
B1177-10Nafamostat
N083-50MGNafamostat Mesylate
10-031Nafamostat . mesylate
AR-N08223-01Nafamostat-d4
285068-01Nafamostat, mesylate
RG-A261465-01Nafamostat Impurity A

Popular Products